DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.

被引：3
|
作者：
Yoon, Jee Sun
Kim, Jin Won
Kim, Ji-Won
Kim, Tae-Yong
Nam, Ah-Rong
Bang, Ju-Hee
Seo, Hye-Rim
Kim, Jae-Min
Oh, Kyoung Seok
Mortimer, Peter G.
Smith, Simon
Oh, Do-Youn
机构：
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Internal Med, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea
[4] AstraZeneca, R&D Oncol, Early Oncol Clin Sci, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS4166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4166
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Biomarker-oriented study of durvalumab in combination with olaparib and paclitaxel in gastric cancer: A phase 2 trial-in-progress.
    Kim, Tae Yong
    Yoon, Jee Sun
    Nam, Ah-Rong
    Bang, Ju-Hee
    Oh, Kyoung Seok
    Seo, Hye-Rim
    Kim, Jae-Min
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
    Kwon, Minsuk
    Kim, Gahyun
    Kim, Ryul
    Kim, Kyu-Tae
    Kim, Seung Tae
    Smith, Simon
    Mortimer, Peter G. S.
    Hong, Jung Yong
    Loembe, Arsene-Bienvenu
    Irurzun-Arana, Itziar
    Koulai, Loumpiana
    Kim, Kyoung-Mee
    Kang, Won Ki
    Dean, Emma
    Park, Woong-Yang
    Lee, Jeeyun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (07)
  • [3] Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
    Kwon, Minsuk
    Kim, Seung Tae
    Hong, Jung Yong
    Kim, Gahyun
    Smith, Simon
    Mortimer, Peter G.
    LoembE, Bienvenu
    Dean, Emma
    Kang, Won Ki
    Lee, Jeeyun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer
    Park, Sehhoon
    Kim, Yu Jung
    Min, Young Joo
    Mortimer, Peter G. S.
    Kim, Hee-Jung
    Smith, Simon A.
    Dean, Emma
    Jung, Hyun Ae
    Sun, Jong-Mu
    Park, Woong-Yang
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Lee, Se-Hoon
    Park, Keunchil
    CANCER, 2024, 130 (04) : 541 - 552
  • [5] Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC).
    Greystoke, Alastair
    Oughton, Jamie B.
    Brown, Sarah R.
    Butterworth, Karl
    Coyle, Victoria
    Franks, Kevin
    Hassani, Adam
    Harrow, Stephen
    Hatton, Matthew
    Hiley, Crispin T.
    Kendall, Jessica
    Phillip, Rachel
    Norris, Matthew
    Ojo, Oluwaseun
    Shaw, Paul
    Walker, Fiona
    Yang, Huiqi
    Chalmers, Anthony J.
    Faivre-Finn, Corinne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
    Kim, Seung Tae
    Smith, Simon A.
    Mortimer, Peter
    Loembe, Arsene-Bienvenu
    Cho, Heejin
    Kim, Kyoung-Mee
    Smith, Claire
    Willis, Sophie
    Irurzun-Arana, Itziar
    Berges, Alienor
    Hong, Jung Yong
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Kozarewa, Iwanka
    Pierce, Andrew J.
    Dean, Emma
    Lee, Jeeyun
    CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4700 - 4709
  • [7] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
    Shah, Payal D.
    Wethington, Stephanie L.
    Pagan, Cheyenne
    Latif, Nawar
    Tanyi, Janos
    Martin, Lainie P.
    Morgan, Mark
    Burger, Robert A.
    Haggerty, Ashley
    Zarrin, Haley
    Rodriguez, Diego
    Domchek, Susan
    Drapkin, Ronny
    Shih, Ie-Ming
    Smith, Simon A.
    Dean, Emma
    Gaillard, Stephanie
    Armstrong, Deborah
    Torigian, Drew A.
    Hwang, Wei-Ting
    Giuntoli, Robert
    Simpkins, Fiona
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 246 - 253
  • [8] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A)
    Simpkins, Fiona
    Nasioudis, Dimitrios
    Wethington, Stephanie L.
    Martin, Lainie P.
    Tanyi, Janos Laszlo
    Latif, Nawar A.
    Torigian, Drew A.
    Omran, Dalia K.
    Rodriguez, Diego
    Smith, Simon
    Dean, Emma
    Domchek, Susan M.
    Drapkin, Ronny
    Shih, Ie-Ming
    Brown, Eric J.
    Hwang, Wei-Ting
    Armstrong, Deborah Kay
    Gaillard, Stephanie
    Giuntoli, Robert Lawrence, II
    Liu, Joyce F.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Randomized phase 2 study of maintenance olaparib vs olaparib plus durvalumab for DNA damage repair (DDR) gene mutated unresectable or metastatic biliary tract cancer (BTC) with durable response to first-line platinum-based chemotherapy: OPTIMUM trial
    Kim, YunJung
    Ok, Boram
    Park, Inkeun
    Ryoo, Baek-Yeol
    Kim, Kyu-Pyo
    Yoo, Changhoon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: phase 3 KEYNOTE-966 trial in progress
    Vogel, A.
    Finn, R.
    Kelley, R.
    Furuse, J.
    Edeline, J.
    Ren, Z.
    Su, S.
    Malhotra, U.
    Siegel, A.
    Valle, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S122 - S122
12345